# Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

> **NCT01526889** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- Non-infectious Intermediate Uveitis
- Non-infectious Posterior Uveitis
- Non-infectious Panuveitis

## Interventions

- **DRUG:** LFG316
- **DRUG:** Conventional Therapy

## Key facts

- **NCT ID:** NCT01526889
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-20
- **Primary completion:** 2017-02-16
- **Final completion:** 2017-08-24
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526889, "Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01526889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*